Cited by 56Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Thioflavin-positive tau aggregates complicating quantification of amyloid plaques in the brain of 5XFAD transgenic mouse model

Open access
Shin, Jisu, Park, Sohui, Lee, HeeYang, Kim, YoungSoo·2021·Scientific Reports

Abstract

Transgenic mouse models recapitulating Alzheimer’s disease (AD) pathology are pivotal in molecular studies and drug evaluation. In transgenic models selectively expressing amyloid-β (Aβ), thioflavin S (ThS), a fluorescent dye with β-sheet binding properties, is widely employed to observe amyloid plaque accumulation. In this study, we investigated the possibility that a commonly used Aβ-expressing AD model mouse, 5XFAD, generates ThS-positive aggregates of β-sheet structures in addition to Aβ fibrils. To test this hypothesis, brain sections of male and female 5XFAD mice were double-stained with ThS and monoclonal antibodies against Aβ, tau, or α-synuclein, all of which aggregates are detected by ThS. Our results revealed that, in addition to amyloid plaques, 5XFAD mice express ThS-positive phospho-tau (p-tau) aggregates. Upon administration of a small molecule that exclusively disaggregates Aβ to 5XFAD mice for six weeks, we found that the reduction level of plaques was smaller in brain sections stained by ThS compared to an anti-Aβ antibody. Our findings implicate that the use of ThS complicates the quantification of amyloid plaques and the assessment of Aβ-targeting drugs in 5XFAD mice.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-021-81304-6

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The 5×FAD transgene does not trigger the late phase formation of neurofibrillary (tau) tangles.

    “In particular, the 5×FAD transgene does not trigger the late phase formation of neurofibrillary (tau) tangles (but see Ref77).”

    From Magnetic resonance microscopy maps widespread effects of Alzheimer’s disease on brain structures and behavior in mice (2026) · cites this paper as [77]

    The Introduction says 5XFAD was designed to develop amyloid pathology, and the Discussion says significant tauopathy was not expected. But the Results report phosphorylated tau aggregates, and the Discussion says further study is needed to determine whether they are neurofibrillary tangles. The paper therefore does not establish the claim that the transgene does not trigger late-phase tangle formation. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 22

  1. [1]Kametani F Hasegawa M Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer's disease Front. Neurosci. 2018 12 25 35 10.3389/fnins.2018.00025 29440986 PMC5797629 · DOI · Paper page
  2. [2]DeVos SL Tau reduction in the presence of amyloid-beta prevents tau pathology and neuronal death in vivo Brain 2018 141 2194 2212 10.1093/brain/awy117 29733334 PMC6022692 · DOI · Paper page
  3. [3]Glenner GG Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts) N. Engl. J. Med. 1980 302 1283 1292 10.1056/NEJM198006053022305 6154243 · DOI
  4. [4]Giasson BI Lee VM Trojanowski JQ Interactions of amyloidogenic proteins Neuromol. Med. 2003 4 49 58 10.1385/NMM:4:1-2:49 14528052 · DOI
  5. [5]Ly, P. T., Cai, F. & Song, W. Detection of neuritic plaques in Alzheimer's disease mouse model. J Vis Exp, e2831–2834 (2011). PMC3197440 21841757
  6. [6]Darvesh S Reid GA Reduced fibrillar beta-amyloid in subcortical structures in a butyrylcholinesterase-knockout Alzheimer disease mouse model Chem. Biol. Interact. 2016 259 307 312 10.1016/j.cbi.2016.04.022 27091549 · DOI
  7. [7]Fernandez T Martinez-Serrano A Cusso L Desco M Ramos-Gomez M Functionalization and characterization of magnetic nanoparticles for the detection of ferritin accumulation in Alzheimer's disease ACS Chem. Neurosci. 2018 9 912 924 10.1021/acschemneuro.7b00260 29298040 · DOI
  8. [9]Okamoto M Riluzole reduces amyloid beta pathology, improves memory, and restores gene expression changes in a transgenic mouse model of early-onset Alzheimer's disease Transl. Psychiatry 2018 8 153 165 10.1038/s41398-018-0201-z 30108205 PMC6092426 · DOI
  9. [10]Saksida T Impaired IL-17 production in gut-residing immune cells of 5xFAD mice with Alzheimer's disease pathology J. Alzheimers Dis. 2018 61 619 630 10.3233/JAD-170538 29254086 · DOI
  10. [11]Svensson M Andersson E Manouchehrian O Yang YY Deierborg T Voluntary running does not reduce neuroinflammation or improve non-cognitive behavior in the 5xFAD mouse model of Alzheimer's disease Sci. Rep. 2020 10 1346 1355 10.1038/s41598-020-58309-8 31992814 PMC6987124 · DOI
  11. [12]Kim HY EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-beta oligomers and plaques Nat. Commun. 2015 6 8997 9010 10.1038/ncomms9997 26646366 PMC4686862 · DOI
  12. [13]Lalowski M The "nonamyloidogenic" p3 fragment (amyloid beta 17–42) is a major constituent of Down's syndrome cerebellar preamyloid J. Biol. Chem. 1996 271 33623 33631 10.1074/jbc.271.52.33623 8969231 · DOI
  13. [14]Rostagno A Ghiso J Isolation and biochemical characterization of amyloid plaques and paired helical filaments Curr. Protoc. Cell Biol. 2009 Chapter 3 1 33 PMC2793596 19731227
  14. [15]Kim HY Kim HV Lee DK Yang SH Kim Y Rapid and sustained cognitive recovery in APP/PS1 transgenic mice by co-administration of EPPS and donepezil Sci. Rep. 2016 6 34165 10.1038/srep34165 27796293 PMC5086916 · DOI
  15. [16]Biernat J The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region EMBO J. 1992 11 1593 1597 10.1002/j.1460-2075.1992.tb05204.x 1563356 PMC556608 · DOI · Paper page
  16. [18]Cho HJ Sharma AK Zhang Y Gross ML Mirica LM A multifunctional chemical agent as an attenuator of amyloid burden and neuroinflammation in Alzheimer's disease ACS Chem. Neurosci. 2020 11 1471 1481 10.1021/acschemneuro.0c00114 32310630 PMC7732605 · DOI
  17. [19]Shukla V A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice FASEB J. 2013 27 174 186 10.1096/fj.12-217497 23038754 PMC3528323 · DOI
  18. [21]Blurton-Jones M Laferla FM Pathways by which Abeta facilitates tau pathology Curr. Alzheimer. Res. 2006 3 437 448 10.2174/156720506779025242 17168643 · DOI
  19. [22]Krivinko JM Koppel J Savonenko A Sweet RA Animal models of psychosis in Alzheimer disease Am. J. Geriatr. Psychiatry 2020 28 1 19 10.1016/j.jagp.2019.05.009 31278012 PMC6858948 · DOI
  20. [23]Moechars D Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain J. Biol. Chem. 1999 274 6483 6492 10.1074/jbc.274.10.6483 10037741 · DOI · Paper page
  21. [24]Stancu IC Vasconcelos B Terwel D Dewachter I Models of beta-amyloid induced Tau-pathology: the long and "folded" road to understand the mechanism Mol. Neurodegener 2014 9 51 64 10.1186/1750-1326-9-51 25407337 PMC4255655 · DOI · Paper page
  22. [25]Sturchler-Pierrat C Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology PNAS 1997 94 13287 13292 10.1073/pnas.94.24.13287 9371838 PMC24301 · DOI · Paper page

Cited by

Sorted by citations

Authors
Shin, J., Park, S., Lee, H., & Kim, Y.
Affiliations
Yonsei University (KR)
Venue
Scientific Reports
Published
2021-01-15
Volume
11
Issue
1
Pages
1617-1617
ISSN
2045-2322 (ISSN-L)
OpenAlex
W3123956652
Cited by
56
References
3
Citations by year
2026: 9 · 2025: 17 · 2024: 9 · 2023: 8 · 2022: 10 · 2021: 3
FWCI
4.71
Type
journal article
Language
en
Open access
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Korea Health Industry Development Institute (HI18C0836)
  • National Research Foundation of Korea (NRF‐2018R1A6A1A03023718)
  • POSCO TJ Park Foundation (POSCO Science Fellowship)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
thioflavin S, amyloid plaques, 5xFAD mice, Alzheimer's disease, amyloid-beta, tau aggregates, phosphorylated tau, beta-sheet, plaque quantification, alpha-synuclein, transgenic mouse model
MeSH terms
Protein Conformation, beta-Strand, Alzheimer Disease, Amyloid, Animals, Brain, Disease Models, Animal, Female, Male, Mice, Transgenic, Phosphorylation, Piperazines, Amyloid beta-Peptides, tau Proteins, Mice, Benzothiazoles, Protein Aggregates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review